<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320941</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066B1201</org_study_id>
    <nct_id>NCT03320941</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity</brief_title>
  <official_title>A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to
      support dose selection for Phase 3 development in Japanese adults with obesity disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">July 23, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Parallel Assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in body weight at 12 week</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>the dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>responder rates according to percent decrease in body weight</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>the responder rates according to percent decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in body weight at 12 week by subgroups</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>the dose-response relationship for weight loss in dysglycemic subjects and subjects with T2DM after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Waist circumference at umbilical level</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Systolic blood pressure (SBP) and diastolic blood pressure (DBP)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP and DBP will be measured three times using the automatic BP monitor and an appropriate size cuff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Fasting lipid profile</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Fasting lipid profile will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on high sensitive C-reactive protein (hsCRP)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Uric acid</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Uric acid will be measured from a blood sample and analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Urine albumin</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Urine albumin will be measured from urine sample and analyzed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on Visceral fat area (VFA)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>VFA by CT scan will be measured at visits and evaluated centrally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on urine albumin to creatinine ratio</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 12 on subcutaneous fat area (SFA)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SFA by CT scan will be measured at visits and evaluated centrally</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>LIK066 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 1 orally for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 2 orally for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 3 orally for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients randomized to this arm will receive LIK066 dose regimen Dose 4 orally for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patient randomized to this arm will receive LIK066 matching placebo orally for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 will be supplied in different doses as tablets to be taken orally.</description>
    <arm_group_label>LIK066 Dose 1</arm_group_label>
    <arm_group_label>LIK066 Dose 2</arm_group_label>
    <arm_group_label>LIK066 Dose 3</arm_group_label>
    <arm_group_label>LIK066 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied as tablets to be taken orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with obesity disease and inadequately controlled body weight with diet and/or
             exercise

          -  BMI ≥ 25 kg/m^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35
             kg/m^2 at least one obesity-related comorbidity

          -  Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%

          -  Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female

          -  Visceral fat area ≥ 100 cm^2

          -  Agreement to comply with the study-required life-style intervention and treatment
             during the full duration of the study

        Exclusion Criteria:

          -  Pregnancy or lactating women

          -  Use of pharmacologically active weight-loss medications

          -  Bariatric surgery

          -  Ketoacidosis, lactic acidosis, hyperosmolar coma

          -  Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to
             screening

          -  Gastro-intestinal (GI) disorders associated with chronic diarrhea

          -  Congestive heart failure, New York Heart Association (NYHA) class III or IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsudo city</city>
        <state>Chiba</state>
        <zip>271 0077</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chikushino-city</city>
        <state>Fukuoka</state>
        <zip>818-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>819-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>807-0857</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kakogawa-city</city>
        <state>Hyogo</state>
        <zip>675-0101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-0863</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto-city</city>
        <state>Kumamoto</state>
        <zip>860-8039</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto city</city>
        <state>Kyoto</state>
        <zip>600-8898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>615-8125</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagasaki city</city>
        <state>Nagasaki</state>
        <zip>850 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Higashiosaka-city</city>
        <state>Osaka</state>
        <zip>577-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Higashiosaka-city</city>
        <state>Osaka</state>
        <zip>577-0803</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ageo-city</city>
        <state>Saitama</state>
        <zip>362-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawaguchi-sity</city>
        <state>Saitama</state>
        <zip>332 0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa-city</city>
        <state>Saitama</state>
        <zip>359-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyogo</city>
        <zip>674-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity disease</keyword>
  <keyword>Over weight</keyword>
  <keyword>T2DM</keyword>
  <keyword>interventional study</keyword>
  <keyword>Weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

